Immunome Inc. (IMNM)
NASDAQ: IMNM
· Real-Time Price · USD
10.26
-0.02 (-0.19%)
At close: Aug 18, 2025, 3:59 PM
10.40
1.41%
After-hours: Aug 18, 2025, 05:41 PM EDT
-0.19% (1D)
| Bid | 9.95 |
| Market Cap | 892.65M |
| Revenue (ttm) | 10.94M |
| Net Income (ttm) | -205.11M |
| EPS (ttm) | -3.05 |
| PE Ratio (ttm) | -3.36 |
| Forward PE | -4.1 |
| Analyst | Buy |
| Ask | 10.49 |
| Volume | 369,219 |
| Avg. Volume (20D) | 903,308 |
| Open | 10.32 |
| Previous Close | 10.28 |
| Day's Range | 10.12 - 10.39 |
| 52-Week Range | 5.15 - 16.73 |
| Beta | 1.93 |
About IMNM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMNM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMNM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Immunome Inc. is scheduled to release its earnings on
Nov 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+7.19%
Immunome shares are trading higher after Lake Stre...
Unlock content with
Pro Subscription
6 months ago
+1.19%
Immunome shares are trading lower after the company announced a $125 million proposed public offering.
2 weeks ago · businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...
